March 11, 2021| Source: PRNewswire Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa (“nemvaleukin”, formerly referred to as…
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
March 11, 2021| Source: PRNewswire Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa (“nemvaleukin”, formerly referred to as…
,
,
A Letter From Our Vice President | February 2021
From the Desk of Alicia Rowell, Vice President Hope, love, cure. That’s our theme this February, in honor of Valentine’s…
What is Oral Parity, and Why Does it Matter?
We answer this question with the help of a pharmacist at a large oncology practice who wishes to remain…
,
Survivor Spotlight: Mark Lewis, Stage III Melanoma Survivor
A Partner Through It All By Mara Klecker Mark Lewis was less than a year into his relationship when he…
,
Art Exhibit to Honor a Friendship and Raise Funds for AIM
By Mara Klecker Melanie Brannan has had difficulty falling asleep in recent weeks. Throughout the day and into the night,…
,
,
Share your Gratitude
Tell us what you are Grateful For……
From the Clinic to the Living Room
Understanding and coping with a new melanoma diagnosis, or melanoma recurrence, can be frightening and overwhelming. AIM’s “Ask a Medical…
Gratitude Wall
Tell Us Something Awesome! We created this virtual Wall of Gratitude to offer the melanoma community an opportunity to express…
Monthly Giving Program
AIM’s Monthly Giving Program, The Supporters Guild Our monthly giving program allows us to fund more critical melanoma research while…
FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
January 24, 2021 19:07 ET | Source: Junshi Biosciences Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical…
,
,
